Neuroscientific Biopharmaceuticals Ltd. ( (AU:NSB) ) has issued an update.
NeuroScientific Biopharmaceuticals Ltd has made significant progress in its IND-enabling studies for EmtinB, a drug aimed at treating advanced glaucoma. The company has initiated studies to evaluate the drug’s safety and pharmacokinetics following a pre-IND meeting with the FDA. Preliminary studies on melanin binding are guiding animal model selection, with further studies scheduled for early 2025. The company’s cash position remains strong at A$4.5 million, supporting ongoing research and development activities. The announcement underscores NeuroScientific’s commitment to expanding its portfolio and advancing its strategic objectives.
More about Neuroscientific Biopharmaceuticals Ltd.
NeuroScientific Biopharmaceuticals Ltd is a company operating in the biopharmaceutical industry, focusing on developing innovative treatments for neurological disorders. The company’s primary product in development is EmtinB, which targets conditions like glaucoma, and it is working towards clinical trials.
YTD Price Performance: 26.67%
Average Trading Volume: 133,245
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$5.49M
Learn more about NSB stock on TipRanks’ Stock Analysis page.